Corti ApS
Stamdata
Navn | Corti ApS |
Adresse | Kuglegårdsvej 2 2, 1434, København K |
Stiftelsesdato | 25. feb. 2014 |
Antal ansatte (CVR) | 60 |
Lokationer (P-enheder) | 1Se lokationer |
Branche | Computerprogrammering (621000) |
Navn | Corti ApS |
Adresse | Kuglegårdsvej 2 2, 1434, København K |
Stiftelsesdato | 25. feb. 2014 |
Antal ansatte (CVR) | 60 |
Lokationer (P-enheder) | 1Se lokationer |
Branche | Computerprogrammering (621000) |
Hold øje med Corti ApS
Beskrivelse
The Company is a vertically AI product & research company focused on the healthcare & life-science industry. Corti enables healthcare providers, payers, life sciences companies, and healthcare-focused independent software vendors (ISVs) to deploy and operate AI-driven clinical workflows - including autonomous agentic systems - without directly managing foundation models, specialized compute infrastructure, clinical validation frameworks, or regulated operating environments. Core platform components include: ● Clinical Model Development and Management: Proprietary and fine-tuned models optimized for healthcare-specific tasks, including clinical speech recognition, ambient documentation, and medical coding, supported by domain-specific evaluation and validation frameworks. ● Agentic Workflow Orchestration: A multi-agent execution layer that enables autonomous operation across clinical workflows, including documentation, coding, and administrative processes, with orchestration logic designed for regulated healthcare environments. ● Compute Orchestration: Abstraction and routing across third-party GPU and cloud providers to optimize cost, performance, and availability in support of AI workload execution at scale. ● Clinical Accuracy and Monitoring: Tooling designed to support continuous evaluation, grounding, and monitoring of AI outputs against clinical quality standards. ● Security and Compliance Enablement: Infrastructure designed to support HIPAA-aligned workflows and other applicable healthcare regulatory requirements, including audit logging, access controls, and data residency capabilities.
Økonomi
| Regnskabsperiode | 2025kr. | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bruttofortjeneste | 1.875.988 | ||||||||
| Driftsresultat | -91.860.880 | ||||||||
| Resultat før skat | -93.266.782 | ||||||||
| Årets resultat | -87.766.782 | ||||||||
| Samlede aktiver | 463.675.763 | ||||||||
| Egenkapital | 347.719.235 | ||||||||
| Gns. ansatte | 73 | ||||||||
2018–2025 Lås regnskabshistorikken op | |||||||||
Datapublica Risk Score
Det indgår i vurderingen
Økonomi
Soliditet, indtjening og likviditet
Regnskaber og historik
Sene regnskaber og tidligere økonomiske problemer
Ejere og ledelse
Tidligere konkurser og ejernes øvrige virksomheder
Virksomhed og relationer
Alder, branche og delte adresser eller kontaktoplysninger
Standard: Score og risikoniveauPro: Også detaljeret forklaring af faktorerne
Gazelle
Henter gazelle-status…
Børsen Gazelle er Dagbladet Børsens kåring. Datapublica er ikke tilknyttet Børsen. Beregnede statusser er Datapublicas egen analyse af offentlige CVR-regnskabsdata.
Ledelse og roller
| Person | Roller | Titler |
|---|---|---|
| Andreas Cleve | Roller BestyrelseDirektion | TitlerBESTYRELSESMEDLEM • DIREKTØR |
| Lars Maaløe | Roller Bestyrelse | TitlerBESTYRELSESMEDLEM |
| Mads Lacoppidan | Roller Bestyrelse | TitlerBESTYRELSESMEDLEM |
| Sara Maria Liliane Rywe | Roller Bestyrelse | TitlerBESTYRELSESMEDLEM |
Revisor
| Revisionsfirma | Revisor | Rolle | Fra |
|---|---|---|---|
| Deloitte Statsautoriseret Revisionspartnerselskab | RevisorClaus Jorch Andersen | RolleState Authorised Public Accountant | Fra4. jun. 2026 |
| Deloitte Statsautoriseret Revisionspartnerselskab | RevisorLeon Thomas Ravn Fagerlind | RolleState Authorised Public Accountant | Fra4. jun. 2026 |
Legale ejere
| Ejer | Ejerandel | Stemmeandel | Fra |
|---|---|---|---|
Unknown Other Participant | Ejerandel10–14,99 % | Stemmeandel10 % | Fra14. sep. 2023 |
| Ejerandel10–14,99 % | Stemmeandel10 % | Fra14. sep. 2023 | |
| Ejerandel10–14,99 % | Stemmeandel10 % | Fra27. jul. 2024 | |
| Ejerandel10–14,99 % | Stemmeandel10 % | Fra18. okt. 2023 | |
Unknown Other Participant | Ejerandel10–14,99 % | Stemmeandel10 % | Fra28. nov. 2023 |
| Ejerandel10–14,99 % | Stemmeandel10 % | Fra14. sep. 2023 | |
| Ejerandel5–9,99 % | Stemmeandel5 % | Fra14. sep. 2023 | |
| Ejerandel5–9,99 % | Stemmeandel5 % | Fra14. sep. 2023 |